Dr. Michel Liuzzi, Director, Early Discovery Program, Institut Pasteur Korea, Republic of Korea will be speaking on the above topic at Drug Discovery World Asia 2012, part of a series of conferences at 5th Annual BioPharma Asia Convention 2012.
Michel Liuzzi, Ph.D., has served as Director, Early Discovery Program at the Institut Pasteur Korea, Seoul (Korea) since January 2011. Prior to that, he was affiliated for 6 years with Idenix Pharmaceuticals Inc., Cambridge (USA) as Senior Director Virology. There he made substantial contributions to the HIV and HCV drug pipeline with the discovery of IDX899, a second generation NNRTI and several direct-acting HCV antivirals. Before joining Idenix, Dr. Liuzzi spent 15 years with Boehringer Ingelheim in Montreal (Canada) as Group Leader Biology, where he was responsible for antiviral research programs on herpes simplex viruses, the human respiratory syncytial virus and the hepatitis C virus. Before entering the pharmaceutical industry, Dr. Liuzzi was a Postdoctoral Fellow at the Cross Cancer Institute, University of Alberta, Edmonton (Canada) where he performed research on enzymatic DNA repair mechanisms. Dr. Liuzzi holds a BSc in Chemistry and a Ph.D. in Biological Chemistry from the University of LiÃ¨ge (Belgium).
Dr Liuzzi will be speaking on the following topics:
1. Effective use of IPK PhenomicScreen and PhenomicID technologies
2. Applications in HCV drug discovery and Alzheimer's disease drug discovery